2nd Quarter - Report

EXPRESS SCRIPTS, INC. for EXPRESS SCRIPTS, INC.

Firm
Client
Income
—
Expenses
$450,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Defense DEF

Issues related to Section 700 (Champus provisions) of the annual National Defense Authorization Act of 2012

LobbyistCovered position, as disclosed
NANCY GILBRIDE —
JONAH C HOUTS —
MARY M ROSADO —

Contacted: Federal Trade Commission (FTC); Executive Office of the President (EOP); White House Office; Labor, Dept of (DOL); Health & Human Services, Dept of (HHS); Internal Revenue Service (IRS); Health Resources & Services Administration (HRSA); Congressional Budget Office (CBO); SENATE; Defense, Dept of (DOD); Government Accountability Office (GAO); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Labor Issues/Antitrust/Workplace LBR

Legislation to exempt certain pharmacies from the antitrust laws for puposes of negotiating with payers (HR 1409, HR 1946, HR 1839)

LobbyistCovered position, as disclosed
JONAH C HOUTS —
ROBERT W LIVELY —
MARY M ROSADO —

Contacted: Centers For Medicare and Medicaid Services (CMS); Internal Revenue Service (IRS); Defense, Dept of (DOD); HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC); White House Office; Labor, Dept of (DOL); Health Resources & Services Administration (HRSA); Government Accountability Office (GAO); Health & Human Services, Dept of (HHS); Congressional Budget Office (CBO); Executive Office of the President (EOP); SENATE

Bills named: H.R. 1409 (112th), H.R. 1839 (112th), H.R. 1946 (112th)

Health Issues HCR

Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs)

LobbyistCovered position, as disclosed
JONAH C HOUTS —
ROBERT W LIVELY —
MARY M ROSADO —

Contacted: Defense, Dept of (DOD); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Labor, Dept of (DOL); Executive Office of the President (EOP); SENATE; White House Office; Government Accountability Office (GAO); Health Resources & Services Administration (HRSA); Internal Revenue Service (IRS); Congressional Budget Office (CBO); Health & Human Services, Dept of (HHS); Federal Trade Commission (FTC)

Medicare/Medicaid MMM

Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General regulatory changes and legislative issues that impact the Part D program such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733).

LobbyistCovered position, as disclosed
JONAH C HOUTS —
ROBERT W LIVELY —
MARY M ROSADO —

Contacted: Government Accountability Office (GAO); Defense, Dept of (DOD); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); SENATE; Centers For Medicare and Medicaid Services (CMS); Congressional Budget Office (CBO); White House Office; Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Internal Revenue Service (IRS); Labor, Dept of (DOL); Federal Trade Commission (FTC)

Bills named: H.R. 905 (112th), H.R. 2248 (112th), H.R. 2190 (112th), H.R. 891 (112th)

Pharmacy PHA

Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (essential health benefits, grandfathering, value-base insurance design, Rx quality, electronic prescribing, PBM disclosure requirements, medical loss ratio); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; Implementation of Zadroga Health Care Act; Legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058)

LobbyistCovered position, as disclosed
JONAH C HOUTS —
ROBERT W LIVELY —
MARY M ROSADO —

Contacted: Internal Revenue Service (IRS); Federal Trade Commission (FTC); Defense, Dept of (DOD); Centers For Medicare and Medicaid Services (CMS); Congressional Budget Office (CBO); White House Office; Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; Labor, Dept of (DOL); Health Resources & Services Administration (HRSA); Government Accountability Office (GAO)

Bills named: H.R. 979 (112th), S. 27 (112th), H.R. 1971 (112th)

Taxation/Internal Revenue Code TAX

HR 4, Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011 Regulatory implementation of various tax provisions in the health reform legislation Repeal of the 3% tax withholding requirement for federal contractors

LobbyistCovered position, as disclosed
JONAH C HOUTS —
ROBERT W LIVELY —
MARY M ROSADO —

Contacted: Congressional Budget Office (CBO); Federal Trade Commission (FTC); White House Office; Health & Human Services, Dept of (HHS); Government Accountability Office (GAO); SENATE; Defense, Dept of (DOD); Health Resources & Services Administration (HRSA); Labor, Dept of (DOL); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Internal Revenue Service (IRS)

Bills named: H.R. 4 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.